

OXiGENE, Inc. VTA Bi-Weekly Teleconference

Meeting Minutes for October 1, 2002

Participants:

Oxigene:

Fred Driscoll
Joe Prezioso
Scott Young
Dai Chaplin
James Velema

Baylor Univ.:

Kevin Pinney
Bob Kane
Charles Garner (unavail.)

Lund University:

Klaus Edvardsen

1.0 Preclinical Update

The next VTA conference call is scheduled for October 22, 2002. Conference calls will be scheduled every other Tuesday at 10:00 a.m. Kevin Pinney prior to the conference call will provide a chemistry summary sheet of compounds worked on at Baylor in the prior three weeks.

Biological Studies

- Klaus performed blood flow shutdown experiments with the indole monophosphate (Oxi3189). The dose levels tested were 200, 400 and 600 mg/kg. Klaus stated that all three concentrations of the indole monophosphate resulted in a ~95% shutdown in tumor blood flow.
- Klaus will initiate an *in vivo* antitumor study with the indole monophosphate (dose for 5 consecutive days). Klaus calculated that he would need ~800 mg of drug in order to perform this study.

CA1

- Kevin and Bob's groups are synthesizing two novel CA1P analogs (2', 3'-diphosphate and 3', 4'-diphosphate). Both compounds lack the methoxy group at the 4' position of the B-ring. Kevin's lab has prepared the ZSB-Target-36 (2',3'-diphosphate-4'-hydrogen) CA-1 analog. The compound (19.2 mg) was shipped to Klaus on 9/3/02. ZSB-Target-36 reduced tumor blood flow by 6% at both the 100 and 10 mg/kg levels. The 3', 4'-diphosphate (4' H; ZSB-Target-37) was shipped (15-20 mg) to Klaus the week of 9/23/02. Klaus will perform MTT and blood flow analysis on this compound.
- Bob Kane's group has resynthesized the 2' fluoro; 3' phosphate; 4' methoxy CA1 analog (ZSB-Target-41). The compound was shipped to Klaus for MTT and blood flow shutdown analysis the week of 9/3/02. ZSB-Target-41 reduced tumor blood flow by 21% and 18% at 100 and 10 mg/kg levels, respectively.